Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-26 @ 2:33 AM
Study NCT ID:
NCT07219602
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-11
First Post:
2025-10-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Sponsor:
NewAmsterdam Pharma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06
Completion Date Type:
ESTIMATED
First Submit Date:
2025-10-20
First Submit QC Date:
None
Study First Post Date:
2025-10-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-11
Last Update Post Date Type:
ESTIMATED